GENÉTICA MOLECULAR EN ONCOHEMATOLOGÍA
Hospital Son Llàtzer
Palma, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Son Llàtzer (11)
2024
-
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
Haematologica, Vol. 109, Núm. 2, pp. 543-552
-
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670
2022
2021
-
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Leukemia Research, Vol. 109
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
2020
-
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. e513-e522
2019
-
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials
European Journal of Haematology, Vol. 102, Núm. 1, pp. 79-86
2016
-
Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy
Leukemia & lymphoma, Vol. 57, Núm. 1, pp. 86-91
-
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327
2014
-
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial
Journal of Clinical Oncology, Vol. 32, Núm. 15, pp. 1595-1604